EDT BioNTech (BNTX) sees FY25 CapEx EUR 250M-EUR 350MDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

BioNTech (BNTX) expects its revenues for the full 2025 financial year to be in the range of EUR 1.7B-EUR 2.2B and revenue phasing similar to ...

The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...

Wall Street futures pointed solidly lower pre-bell Monday as traders weighed undulating Washington tariff plans, war in Eastern Europe and reports of a possibly slowing US economy. In the futures, the ...

SVB Wealth LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the fourth quarter, Holdings ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Three ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Canaccord Genuity analyst William Maughan maintained a Buy rating and increased the price target from $171 to $171.44 on Nov. 27, 2024. This analyst has an accuracy rate of 71%. JP Morgan analyst ...

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...

German biotech major BioNTech (Nasdaq: BNTX) has suffered a blow as it seeks to add new revenue streams beyond its COVID-19 ...